Rekvina Laboratories Limited has submitted its quarterly compliance certificate to BSE Limited under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the fourth quarter of fiscal year 2026. The certificate, dated 06.04.2026, covers the period from 1st January, 2026 to 31st March, 2026.

Regulatory Compliance Filing

The compliance certificate was signed by Shah Surbhit Mukeshbhai, Director of Rekvina Laboratories Limited (DIN: 01993300), and submitted to the Department of Corporate Services at BSE Limited. The company trades under scrip code 526075 on the exchange.

Registrar and Transfer Agent Confirmation

M/s. Purva Sharegistry India Pvt. Ltd, serving as the company's Registrar and Share Transfer Agent, provided the compliance certificate. The agency, registered with SEBI under registration number INR000001112 as Category 1 Registrars to IPO & Share Transfer Agents, confirmed adherence to regulatory requirements for dematerialisation processes.

Ms. Deepali Gaonkar, Compliance Officer at Purva Sharegistry, certified that all securities received from depository participants during the quarter were properly processed and confirmed to depositories within prescribed timelines. The certificate also confirms that security certificates received for dematerialisation were mutilated and cancelled after due verification.

Dematerialisation Activity Summary

The quarterly report reveals no dematerialisation activity during the Q4FY26 period. The detailed breakdown shows:

This indicates that no shareholders opted to convert their physical share certificates to electronic form during the January-March 2026 quarter. The 'NIL' entries across all categories in the dematerialisation details table confirm zero activity in this regard.

Regulatory Framework

The filing ensures compliance with SEBI's quarterly reporting requirements under the Depositories and Participants Regulations, 2018. These regulations mandate that companies submit confirmation certificates regarding their dematerialisation activities, ensuring transparency in the conversion process from physical to electronic securities. The timely submission demonstrates Rekvina Laboratories' commitment to regulatory compliance and corporate governance standards.

Rekvina Laboratories Limited has published its detailed public statement for the mandatory open offer launched by three acquirers seeking to acquire a significant stake in the Gujarat-based pharmaceutical company.

Open Offer Details

Surbhit Mukesh Shah, Amit Mukesh Shah, and Dhruvalkumar Patel are jointly making the open offer to acquire up to 28,90,100 equity shares of Rekvina Laboratories at ₹10.00 per share. The offer represents 26% of the company's expanded share capital and involves a total consideration of ₹2,89,01,000, assuming full acceptance.

Background Transaction

The mandatory open offer was triggered by the execution of a Securities Exchange and Purchase Agreement (SEPA) on March 16, 2026. Under this agreement, Rekvina Laboratories will acquire 100% equity stake in Radiant Parenterals Limited for ₹4,62,77,500 through a share swap mechanism.

The board of directors approved issuing 46,27,750 equity shares of ₹5.00 face value each at ₹10.00 per share to discharge the acquisition consideration. The transaction was valued based on an independent valuation report determining the fair value of Rekvina's equity shares at ₹10.00 per share, establishing a swap ratio of 2.5 Rekvina shares for every Radiant share.

Acquirer Profiles

Surbhit Mukesh Shah (Acquirer-1) currently holds 9,17,607 equity shares (15.22% stake) and serves as Executive Director and Chief Financial Officer. His net worth as of February 28, 2026 stands at ₹56,93,09,231.10.

Amit Mukesh Shah (Acquirer-2) holds 8,27,883 equity shares (13.73% stake) and serves as Managing Director. His net worth as of February 28, 2026 is ₹46,16,41,790.67.

Dhruvalkumar Patel (Acquirer-3) currently holds no shares in the target company but will be reclassified as a promoter following the SEPA consummation. His net worth as of February 16, 2026 is ₹17,07,48,405.

Financial Arrangements

The acquirers have established robust financial arrangements to support the open offer. They have deposited ₹72,25,250 in an escrow account with ICICI Bank Limited, representing 25% of the maximum consideration as required under SEBI regulations.

Offer Timeline

The open offer follows a structured timeline with key milestones spread across several months. The tendering period is scheduled from May 14, 2026 to May 27, 2026, with BSE Limited serving as the designated stock exchange.

Company Overview

Rekvina Laboratories Limited, incorporated in 1988, is engaged in manufacturing and marketing pharmaceutical products. The company's equity shares are listed on BSE Limited with security code 526075. The authorized share capital stands at ₹3,50,00,000 comprising 70,00,000 equity shares of ₹5.00 face value each.

The company's recent financial performance shows total revenue of ₹54.18 lakhs for the period ended December 31, 2025, though it reported a net loss of ₹19.42 lakhs during the same period.

Post-Offer Shareholding

Upon completion assuming full acceptance, the acquirers will collectively hold 85,95,652 equity shares representing 77.33% of the expanded share capital. Combined with existing promoter group members, the total promoter holding will reach 1,00,07,333 shares or 90.03% of the expanded share capital.

The acquirers have confirmed their intention to retain the company's listing status and have no immediate plans for delisting. However, the transaction will result in public shareholding falling below the minimum 25% requirement, necessitating compliance with relevant regulations to restore adequate public float.